Business Context and Reporting Period
Company: Voyager Therapeutics, Inc. (VYGR)
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2026
Event: Presentation of Good Laboratory Practice (GLP) toxicology data for investigational gene therapy VY1706 at the Alzheimer's Association International Conference.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a specific corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Updates
- GLP Toxicology Results: Data presented for VY1706 (tau silencing gene therapy for Alzheimer's disease) in non-human primates (NHPs) showed a favorable tolerability profile up to the highest dose tested (5 x 1013 vector genomes/kg).
- Safety Findings: No adverse clinical pathology or histopathological findings were observed in the central nervous system (CNS), dorsal root ganglia, or peripheral organs (including liver).
- Efficacy Data: A single intravenous dose achieved broad, durable, and dose-dependent CNS delivery, resulting in up to 75% lowering of microtubule-associated protein tau (MAPT) mRNA and tau protein in key brain regions through six months.
- Mechanism of Action: The study identified ALPL as a receptor mediating blood-brain barrier transport, supporting cross-species translatability.
- Regulatory Status: The Company received U.S. FDA Investigational New Drug (IND) clearance for VY1706 in June 2026.
Guidance, Outlook, and Risks
Outlook: Management plans to begin dosing in a multi-site, open-label, dose-escalation clinical trial of VY1706 in the second half of 2026.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Uncertainty regarding the initiation, enrollment, timing, and results of clinical trials.
- Regulatory decisions and the ability to replicate preclinical results in humans.
- Potential adverse events impacting development.
- Sufficiency of cash resources to fund operations and corporate objectives.
- Technical hurdles in development, manufacture, and supply.
Investor Verification Checklist
- Confirm the specific start date of the VY1706 clinical trial within the second half of 2026.
- Review the Company's most recent Form 10-K or 10-Q to assess current cash runway and liquidity status.
- Monitor subsequent filings for updates on clinical trial enrollment and any safety signals from the first-in-human dosing.
- Verify the status of intellectual property rights related to the ALPL receptor mechanism and VY1706.